Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment

In recent years, targeted therapy and immunotherapy have played important roles in the treatment of patients with non-small-cell lung cancer (NSCLC). Drugs that target epidermal growth factor receptor (EGFR) mutations (eg, gefitinib, erlotinib, icotinib, and osimertinib) are among the most commonly...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Hongge, Liu, Xiaoyan, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163004/
https://www.ncbi.nlm.nih.gov/pubmed/30288054
http://dx.doi.org/10.2147/OTT.S178497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163004/
https://www.ncbi.nlm.nih.gov/pubmed/30288054
http://dx.doi.org/10.2147/OTT.S178497

Ejemplares similares